Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants

John B. Hiebert, Qiuhua Shen, Amanda Thimmesch and Janet Pierce

University of Kansas, School of Nursing, Kansas, USA

Abstract: Heart failure with preserved ejection fraction (HFpEF) is a significant cardiovascular condition for more than 50% of patients with heart failure. Currently, there is no effective treatment to decrease morbidity and mortality rates associated with HFpEF because of its pathophysiological heterogeneity. Recent evidence shows that deficiency in myocardial bioenergetics is one of the key pathophysiological factors contributing to diastolic dysfunction in HFpEF. Another known mechanism for HFpEF is an overproduction of free radicals, specifically reactive oxygen species. To reduce free radical formation, antioxidants are often used. This article is a summative review of the recent relevant literature that addresses cardiac bioenergetics, deficiency in myocardial bioenergetics, and increased reactive oxygen species associated with HFpEF and the promising potential use of antioxidants in managing this condition.

Keywords: Adenosine triphosphate, Antioxidants, Bioenergetics, Diastolic heart failure, Free radicals, Heart failure with preserved ejection fraction.

1. BACKGROUND

Heart failure (HF) is a serious, progressive cardiovascular disease in which the myocardium is unable to pump sufficient blood to meet the body’s demand. In the United States, approximately 5.1 million people have HF which is estimated to cost the nation about $32 billion each year.

An individual with HF has problems related to functional or structural impairment of ventricular filling or ejection of blood from the heart. Patients with HF are often classified based on ejection fraction (EF) in terms of either preserved or reduced EF. Thus, systolic HF is referred to as heart failure with reduced ejection fraction (HFrEF), and diastolic HF is referred to as heart failure with preserved ejection fraction (HFpEF) [1]. Approximately 50% of the patients with HF have HFpEF and they have higher morbidity and mortality rates than patients with HFrEF. Some clinicians believe that HFpEF is an emerging epidemic because of the rising prevalence in patients over the age of 65 and the lack of treatment for impaired myocardial energy availability [2].

The most recent guidelines related to the management of HF were published in 2013 by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA). This document includes discussion about the challenge of diagnosing patients with HFpEF because of the many causes of their symptoms; however, there is no mention of myocardial bioenergetics. There is a brief discussion of nutritional supplements and hormonal therapies but it is suggested that more data are needed before recommendations for HFpEF treatment are made [1].

For patients with HFpEF activation of the sympathetic nervous system and the renin angiotensin system can cause elevation in the production of free radicals, particularly reactive oxygen species (ROS) in the myocardium. This increase in ROS leads to excess oxidative stress that damages the myocardium. In addition to the increase in ROS,
impairment of the mitochondrial bioenergetics leads to decreased adenosine triphosphate (ATP) production [3]. Both of these factors are now believed to be major mechanisms for the development of HFpEF [4 - 6]. In this article we will specifically review how increasing myocardial bioenergetics and supplementing antioxidants are potential additional treatments for HFpEF.

2. MYOCARDIAL BIOENERGETICS

Bioenergetics is a broad term used to describe energy transactions and transformations [7]. Compared to cells in any other organ, cell in the myocardium consume the most energy. Although the myocardium can generate ATP utilizing a variety of substrates, the vast majority of ATP is synthesized in the electron transport chain (ETC) of mitochondria in the form of ATP or phosphocreatine (PCr). The myocardial consumption of ATP is approximately 1 nM ATP per second, and myocardial energy stores must be regenerated about every 20 seconds in order to meet the high demand for ATP in the heart [8]. Relevant to HFpEF, diastolic myocardial consumption of ATP exceeds systolic ATP consumption [9].

An important component of myocardial energetics is calcium, which plays a role in the regulation of ATP synthesis and in consumption associated with myocardial contraction and relaxation [10]. During excitation-contraction, calcium is released from the sarcoplasmic reticulum and then binds to troponin C, causing displacement of tropomyosin and allowing actin-myosin cross-bridging. The thick and thin filaments of the sarcomere are then able to slide past each other, resulting in cardiac muscle contraction. In contrast, reuptake of calcium back to the sarcoplasmic reticulum contributes to the relaxation of cardiac muscle, an active process requiring ATP. In HFpEF, there is a leak and impaired uptake of calcium that leads to profound alterations in cardiac contractility [11].

There are significant changes in the bioenergetics of the myocardial mitochondria with age. Over time, ROS damage occurs mainly in Complex I of the ETC within mitochondria [12]. This damage results in energy decline associated with impaired early diastolic filling. There is increased myocardial torsion to shortening ratio and a reduction in the PCR to ATP ratio. The consequence of these alterations in the myocardial mitochondria is the pathophysiologic basis of HFpEF [13]. Myocardial energy deficiency underlies the disruption of myocardial bioenergetics that leads to HFpEF [8].

3. REACTIVE OXYGEN SPECIES AND ANTIOXIDANTS

Free radicals are unstable and highly reactive molecules with unpaired electrons. These molecules can either accept or donate electrons from or to other molecules, and this produces either reductants or oxidants. Often the oxidant is termed a ROS to describe a superoxide (O_2^− ●) or hydroxyl radical (OH^●). For proper physiologic balance there must be equilibrium between free radicals and antioxidants. If ROS are overproduced, they can damage parts of the cell such as the proteins, lipids, and DNA. When there is an overabundance of ROS and the body’s antioxidant system is unable to regulate the free radicals, oxidative stress occurs [14, 15]. There is evidence suggesting that excessive oxidative stress causes damage to the myocardium in patients with HFpEF [16, 17].

In the cardiac myocytes, approximately 90% of the ATP is produced from the mitochondria. The mitochondria are a major source of ROS in the myocardium representing byproducts of oxidative phosphorylation. In myocardial mitochondria, the major O_2^− ● is mainly produced by electron leakage from the ETC. A decrease in mitochondrial phosphorylation then increases electron leakage from the ETC and consequently produces hydrogen peroxide (H_2O_2) that is then converted to the highly damaging OH^●. Consequently, there is oxidative stress from the overproduction of mitochondrial ROS that has been associated with many cardiac diseases including HFpEF [18].

Patients with HFpEF have elevated ROS levels that contributes to the hypertrophy and increased resting tension in cardiomyocytes [19]. In numerous studies researchers have investigated the various molecular pathways related to ROS production in HFpEF [20, 21]. Hirata et al. recently used a novel biomarker called derivatives of reactive oxidative metabolite (DROM) and found that increased DROM was an independent and significant predictor of cardiovascular events in HFpEF. Specifically there was an association between the increased DROM levels and severity of HFpEF [20]. This is an example of a potential useful biomarker to measure ROS concentrations in patients with HFpEF.

Using an antioxidant to counteract increased free radical production is a potential method to reduce myocardial injury in patients with HFpEF. In both animal [21, 22] and human studies researchers have investigated the effects of antioxidant therapy to improve myocardial function in HFpEF. Wilder et al. found in studies with mice that the oxidative myofilament modifications are an important mediator in diastolic function. They administered an antioxidant
called N-acetylcysteine (NAC) for 30 days and discovered that NAC reversed baseline diastolic dysfunction and hypertrophy [23]. However, many large clinical trials related to HF have failed to demonstrate a significant difference with antioxidants such as vitamin C or vitamin E [24]. This could be because these agents do not have a specific target for mitochondrial ROS generation. Thus, investigating antioxidant compounds such as coenzyme Q10 that target mitochondrial ROS is promising for future supplemental treatment of HFpEF [3]. A meta-analysis of coenzyme Q10 randomized clinical trials found that it improves outcomes of HF patients. Since coenzyme Q10 is an integral component of the mitochondrial respiratory chain for ATP production and also an antioxidant, coenzyme Q10 could assist in improving myocardial function in HF patients [25].

4. MANAGEMENT OF HFpEF

The principal symptoms of HFpEF include exertional shortness of breath and fatigue [26]. The majority of patients with HFpEF are older women with a history of hypertension. In addition, these patients have many comorbidities such as obesity, diabetes mellitus, dyslipidemia, and coronary artery disease [27, 28]. The 2013 ACCF/AHA Guideline for the Management of Heart Failure recommends the use of diuretics for symptoms of volume overload and beta-blocking agents, angiotensin-receptor enzyme (ACE) inhibitors, and angiotensin-receptor blockers (ARB) for hypertension [1]. Nevertheless, there are no pharmaceutical agents that have altered the clinical course of HFpEF.

Studies have indicated that moderate walking exercise for patients with HFpEF is associated with improved symptoms of fatigue and shortness of breath, and with weight loss and improved quality of life. However, exercise may not change the patient’s systolic or diastolic function [29 - 31]. Adjunctive therapy such as omega-3 polyunsaturated fatty acids [32, 33], coenzyme Q10 [34], and D-ribose [35] supplementation have been found useful for reducing the symptoms of HFpEF. Further research is needed because the recommended management of HFpEF has not been effective in reversing the poor prognosis for these patients. The absence of effective therapeutic strategies may be related to the heterogeneity of HFpEF pathophysiology and to inadequate emphasis placed on myocardial bioenergetics.

Below is a summary of the key messages expressed in this article (Table 1).

Table 1. Key messages.

| Message                                                                 |
|------------------------------------------------------------------------|
| • HFpEF activates sympathetic nervous system and the renin angiotensin   |
| system causing increased free radical production.                      |
| • There are currently no pharmaceutical agents that have altered the   |
|    clinical course of HFpEF.                                            |
| • There is a decline in myocardial bioenergetics with aging.            |
| • Patients with HFpEF have elevated reactive oxygen species (ROS) which |
|    impairs mitochondrial bioenergetics.                                 |
| • Several antioxidants such as ubiquinol reduce ROS production and      |
|    improve myocardial energetics.                                       |
| • Antioxidant augmentation could potentially reduce the incidence of    |
|    HFpEF.                                                              |

CONCLUSION

Myocardial bioenergetics deficiency is proposed as one of the key underlying mechanisms contributing to the development of HFpEF in patients. This is supported by recent literature showing that enhancing myocardial bioenergetics could potentially be effective in reducing the incidence of HFpEF [36]. Additional research is needed to investigate the effects of using antioxidants (e.g., coenzyme Q10) to assist with the insufficient cardiac bioenergetics in HFpEF. The use of antioxidant therapies could be a potential supplemental treatment in patients with HFpEF that would optimize their overall health.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

Declared none.

REFERENCES

[1] Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147-239. [http://dx.doi.org/10.1016/j.jacc.2013.05.019] [PMID: 23747642]
[2] Oktay AA, Rich JD, Shah SJ. The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep 2013; 10(4): 401-10. [http://dx.doi.org/10.1007/s11897-013-0155-7] [PMID: 24078336]

[3] Münzel T, Gori T, Keaney JF Jr, Maack C, Daiber A. Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications. Eur Heart J 2015; 36(38): 2555-64. [http://dx.doi.org/10.1093/eurheartj/ehv305] [PMID: 26142467]

[4] Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep 2014; 16(7): 501. [http://dx.doi.org/10.1007/s11886-014-0501-8] [PMID: 24893938]

[5] van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 2012; 126(7): 830-9. [http://dx.doi.org/10.1161/CIRCULATIONAHA.111.076075] [PMID: 22806632]

[6] Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62(4): 263-71. [http://dx.doi.org/10.1016/j.jacc.2013.02.092] [PMID: 23684677]

[7] Kresge N Sr, Hill R. Historical Perspectives: Bioenergetics. J Biochem 2010; 285: 1.

[8] Ventura-Clapier R, Garnier A, Veksler V, Joubert F. Bioenergetics of the failing heart. Biochim Biophys Acta 2011; 1813: 1360-72.

[9] Sinatra ST. Metabolic cardiology: an integrative strategy in the treatment of congestive heart failure. Altern Ther Health Med 2009; 15(3): 44-52. [PMID: 19472864]

[10] Glancy B, Balaban RS. Role of mitochondrial Ca\(^{2+}\) in the regulation of cellular energetics. Biochemistry 2012; 51(14): 2959-73. [http://dx.doi.org/10.1021/bi2018909] [PMID: 24443365]

[11] Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 2013; 123(1): 46-52. [http://dx.doi.org/10.1172/JCI62834] [PMID: 23281409]

[12] Akhmedov AT, Rybin V, Marin-Garcia J. Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. Heart Fail Rev 2015; 20(2): 227-49. [http://dx.doi.org/10.1007/s10741-014-9457-4] [PMID: 25913222]

[13] Zuo L, Chuang CC, Hemmelgarn BT, Best TM. Heart failure with preserved ejection fraction: Defining the function of ROS and NO. J Appl Physiol 2015; 119(8): 944-51. [http://dx.doi.org/10.1152/japplphysiol.00149.2014] [PMID: 25977452]

[14] Zambrano S, Blanca AJ, Ruiz-Armenta MV, et al. L-Carnitine protects against arterial hypertension-related cardiac fibrosis through modulation of PPAR-γ expression. Biochem Pharmacol 2013; 85(7): 937-44. [http://dx.doi.org/10.1016/j.bcp.2012.02.011] [PMID: 23295156]

[15] Gori T, Münzel T. Oxidative stress and endothelial dysfunction: therapeutic implications. Ann Med 2011; 43(4): 259-72. [http://dx.doi.org/10.3109/07853890.2010.545920] [PMID: 21284528]
[25] Fotino AD, Thompson-Paul AM, Bazzano LA. Effect of coenzyme Q(1)(0) supplementation on heart failure: a meta-analysis. Am J Clin Nutr 2013; 97(2): 268-75. [http://dx.doi.org/10.3945/ajcn.112.040741] [PMID: 23221577]

[26] van Heerebeek L, Franssen CP, Hamandi N, Verheugt FW, Somsen GA, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 2012; 9(4): 293-302. [http://dx.doi.org/10.1007/s11897-012-0109-5] [PMID: 22926993]

[27] Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355(3): 251-9. [http://dx.doi.org/10.1056/NEJMoa0525256] [PMID: 16855265]

[28] Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119(24): 3070-7. [http://dx.doi.org/10.1161/CIRCULATIONAHA.108.815944] [PMID: 19506115]

[29] Pandey A, Parashar A, Kumbhani DJ, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail 2015; 8(1): 33-40. [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.114.001615] [PMID: 25399909]

[30] Kitzman DW, Brubaker PH, Herrington DM, et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J Am Coll Cardiol 2013; 62(7): 584-92. [http://dx.doi.org/10.1016/j.jacc.2013.04.033] [PMID: 23665370]

[31] Fleg JL, Cooper LS, Borlaug BA, et al. National Heart, Lung, and Blood Institute Working Group. Exercise training as therapy for heart failure: current status and future directions. Circ Heart Fail 2015; 8(1): 209-20. [http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.001420] [PMID: 25605639]

[32] Macchia A, Levantesi G, Franzosi MG, et al. GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. Eur J Heart Fail 2005; 7(5): 904-9. [http://dx.doi.org/10.1016/j.ejheart.2005.04.008] [PMID: 16087142]

[33] Tavazzi L, Maggioni AP, Marchioli R, et al. Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9654): 1223-30. [http://dx.doi.org/10.1016/S0140-6736(08)61239-8] [PMID: 18757090]

[34] Mortensen SA, Rosenfeldt F, Kumar A, et al. Q-SYMBIO Study Investigators. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014; 2(6): 641-9. [http://dx.doi.org/10.1016/j.jchf.2014.06.008] [PMID: 25282031]

[35] Bayram M, St Cyr JA, Abraham WT. D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Ther Adv Cardiovasc Dis 2015; 9(3): 56-65. [http://dx.doi.org/10.1177/1753944715572752] [PMID: 25701016]

[36] Rodrigues PG, Leite-Moreira AF, Facalcao-Pires I. Myocardial reverse remodeling: how far can we rewind? AJP-Heart and Circulatory Physiology. 2016; 310(11): 402-22. [http://dx.doi.org/10.1152/ajpheart.00696.2015]